GLP-1 drugs for obstructive sleep apnea: a new review positions them as an adjunct to CPAP

Pulmonology Advisor has reported on a review by Harris and Kaffenberger, published online September 3, 2026, in JAMA Otolaryngology–Head & Neck Surgery, on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obstructive sleep apnea (OSA) in adults with obesity ^[1]. The authors examined tirzepatide, semaglutide, liraglutide, exenatide and retatrutide. They concluded that these drugs improve OSA mainly through weight loss but reduce breathing events less than continuous positive airway pressure (CPAP), the traditional device-based treatment ^[1].

What the review draws on

As reported, the review examined earlier meta-analyses, phase 3 trials and cohort data ^[1].

• Across 6 earlier meta-analyses, GLP-1 RA use reduced the apnea-hypopnea index (AHI) by 5.7 to 21.9 events per hour. AHI is the hourly frequency of apnea and hypopnea events during sleep ^[1].
• The phase 3 SURMOUNT-OSA trials compared tirzepatide with placebo in adults with moderate to severe OSA and obesity. Tirzepatide reduced AHI by about 20 to 24 events per hour, with average weight loss of 18% to 20% ^[1].
• In those trials, 42% to 50% of patients reached remission, defined as an AHI below 5 events per hour, or below 15 events per hour without symptoms ^[1].
• The SURMOUNT-OSA results were the basis for the US Food and Drug Administration's approval of tirzepatide for moderate to severe OSA in adults with obesity toward the end of 2024 ^[1].

The story does not report enrollment numbers, confidence intervals or p-values for the trials or meta-analyses ^[1].

Mechanism: mostly weight

The authors attribute most of the benefit to weight loss, citing studies showing the drugs reduce tongue fat and parapharyngeal adipose tissue, both involved in upper airway collapse ^[1]. In the Wisconsin Sleep Cohort Study, a 10% increase in body weight was associated with a 32% increase in AHI, and a 10% weight loss with a 26% reduction ^[1]. The authors also raise possible weight-independent effects, including GLP-1 receptor signaling in the carotid body, leptin pathway interactions and NLRP3 inflammasome suppression, and describe this evidence as preclinical ^[1].

Why it matters for surgical and weight-management patients

The review places these drugs beside CPAP rather than in place of it. A prior umbrella review found AHI reductions of roughly 31 events per hour with CPAP versus 22 with tirzepatide ^[1]. The authors describe GLP-1 RAs as "best positioned as complementary therapy alongside CPAP, preoperative optimization before upper airway surgery" ^[1]. They add a more tentative role: possibly widening the group of patients who qualify for a hypoglossal nerve stimulator ^[1].

The authors described GLP-1 RAs as appropriate for patients with a body mass index (BMI) above 30 who tolerate CPAP poorly and have obesity-related comorbidities ^[1]. They judged the drugs unsuitable for people without obesity, for primarily anatomic obstruction, and for central sleep apnea ^[1].

AthleticsMD offers PREOOP surgical pre-optimization programs and ShredRx physician-guided medical weight loss ^{[AthleticsMD]}. The review's proposed use before upper airway surgery overlaps with pre-optimization care, although the story reports no data on how preoperative GLP-1 RA treatment affects surgical outcomes ^{[1][AthleticsMD]}.

What to watch next

The authors flag several open questions ^[1]:

• whether the drugs change cardiovascular outcomes in this population ^[1];
• how much weight returns after treatment stops ^[1];
• whether tirzepatide is cost-effective for OSA, since available data suggest it may not be under commonly used thresholds ^[1];
• whether the drugs can in practice expand hypoglossal nerve stimulator candidacy, which the authors present only as a potential use ^[1].

Limitations

The article is secondary reporting on a review and notes that it originally appeared on Endocrinology Advisor ^[1]. The story does not say whether the review used a systematic search, and it gives no data showing that preoperative GLP-1 RA treatment changes upper airway surgery outcomes, so that role remains a proposal from the authors ^[1]. The Wisconsin findings come from a cohort study and do not on their own establish that weight change causes changes in AHI ^[1]. One author declared affiliations with biotech, pharmaceutical or device companies ^[1].